Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, comments on the optimization of chemotherapy combinations for the treatment of acute myeloid leukemia (AML), highlighting the importance of considering the safety profile. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.